Innate lymphoid cells involve in tumorigenesis

International Journal of Cancer

Volumn 138, Issue 1, 2016, Pages 22-29

  Tian, Zhiqiang ^a   Van Velkinburgh, Jennifer C ^b   Wu, Yuzhang ^a   Ni, Bing ^a  

^a THIRD MILITARY MEDICAL UNIVERSITY   (China)

^b Van Velkinburgh Initiative for Collaboratory BioMedical Research   (United States)

Author keywords

cancer; cytokine; IL 17; IL 22; innate lymphoid cells; Th1; Th2

Indexed keywords

INTERLEUKIN 33; INTERLEUKIN 5;

ARTICLE; BILE DUCT CARCINOMA; BREAST CANCER; CANCER DIAGNOSIS; CANCER PROGNOSIS; CANCER THERAPY; CARCINOGENESIS; CELL FUNCTION; HUMAN; LYMPHOID CELL; METASTATIC MELANOMA; NONHUMAN; PHENOTYPE; PRIORITY JOURNAL; ANIMAL; CELL TRANSFORMATION; GENETICS; IMMUNOLOGY; LYMPHOCYTE SUBPOPULATION; METABOLISM; NEOPLASMS;

ANIMALS; CELL TRANSFORMATION, NEOPLASTIC; HUMANS; LYMPHOCYTE SUBSETS; NEOPLASMS; PHENOTYPE;

EID: 84944280967     PISSN: 00207136     EISSN: 10970215     Source Type: Journal    
DOI: 10.1002/ijc.29443     Document Type: Article

References (97)

1. Constantinides MG, McDonald BD, Verhoef PA, et al., A committed precursor to innate lymphoid cells. Nature 2014; 508: 397-401.
2. Fuchs A, Colonna M., Innate lymphoid cells in homeostasis, infection, chronic inflammation and tumors of the gastrointestinal tract. Curr Opin Gastroenterol 2013; 29: 581-7.
3. Spits H, Artis D, Colonna M, et al., Innate lymphoid cells-a proposal for uniform nomenclature. Nat Rev Immunol 2013; 13: 145-9.
4. Montaldo E, Vacca P, Moretta L, et al., Development of human natural killer cells and other innate lymphoid cells. Semin Immunol 2014; 26: 107-13.
5. Klose CS, Flach M, Mohle L, et al., Differentiation of type 1 ILCs from a common progenitor to all helper-like innate lymphoid cell lineages. Cell 2014; 157: 340-56.
6. Yagi R, Zhong C, Northrup DL, et al., The transcription factor GATA3 is critical for the development of all IL-7Ralpha-expressing innate lymphoid cells. Immunity 2014; 40: 378-88.
7. Serafini N, Klein Wolterink RG, Satoh-Takayama N, et al., Gata3 drives development of RORgammat+ group 3 innate lymphoid cells. J Exp Med 2014; 211: 199-208.
8. Spits H, Di Santo JP., The expanding family of innate lymphoid cells: Regulators and effectors of immunity and tissue remodeling. Nat Immunol 2011; 12: 21-7.
9. Jovanovic IP, Pejnovic NN, Radosavljevic GD, et al., Interleukin-33/ST2 axis promotes breast cancer growth and metastases by facilitating intratumoral accumulation of immunosuppressive and innate lymphoid cells. Int J Cancer 2013; 134: 1669-82
10. Moro K, Yamada T, Tanabe M, et al., Innate production of T(H)2 cytokines by adipose tissue-associated c-Kit(+)Sca-1(+) lymphoid cells. Nature 2010; 463: 540-4.
11. Liu J, Duan Y, Cheng X, et al., IL-17 is associated with poor prognosis and promotes angiogenesis via stimulating VEGF production of cancer cells in colorectal carcinoma. Biochem Biophys Res Commun 2011; 407: 348-54.
12. Kirchberger S, Royston DJ, Boulard O, et al., Innate lymphoid cells sustain colon cancer through production of interleukin-22 in a mouse model. J Exp Med 2013; 210: 917-31.
13. Spits H, Cupedo T., Innate lymphoid cells: Emerging insights in development, lineage relationships, and function. Ann Rev Immunol 2012; 30: 647-75.
14. Fuchs A, Vermi W, Lee JS, et al., Intraepithelial type 1 innate lymphoid cells are a unique subset of IL-12- and IL-15-responsive IFN-gamma-producing cells. Immunity 2013; 38: 769-81.
15. Bernink JH, Peters CP, Munneke M, et al., Human type 1 innate lymphoid cells accumulate in inflamed mucosal tissues. Nat Immunol 2013; 14: 221-9.
16. Deguine J, Bousso P., Dynamics of NK cell interactions in vivo. Immunol Rev 2013; 251: 154-9.
17. Sojka DK, Plougastel-Douglas B, Yang L, et al., Tissue-resident natural killer (NK) cells are cell lineages distinct from thymic and conventional splenic NK cells. eLife 2014; 3: E01659.
18. Daussy C, Faure F, Mayol K, et al., T-bet and Eomes instruct the development of two distinct natural killer cell lineages in the liver and in the bone marrow. J Exp Med 2014; 211: 563-77.
19. Gasteiger G, Hemmers S, Firth MA, et al., IL-2-dependent tuning of NK cell sensitivity for target cells is controlled by regulatory T cells. J Exp Med 2013; 210: 1167-78.
20. Peng H, Jiang X, Chen Y, et al., Liver-resident NK cells confer adaptive immunity in skin-contact inflammation. J Clin Invest 2013; 123: 1444-56.
21. Leavy O., Innate-like lymphocytes: Will the real ILC1 please stand up? Nat Rev Immunol 2013; 13: 67.
22. Maloy KJ, Uhlig HH., ILC1 populations join the border patrol. Immunity 2013; 38: 630-2.
23. Mjosberg J, Bernink J, Golebski K, et al., The transcription factor GATA3 is essential for the function of human type 2 innate lymphoid cells. Immunity 2012; 37: 649-59.
24. Hoyler T, Klose CS, Souabni A, et al., The transcription factor GATA-3 controls cell fate and maintenance of type 2 innate lymphoid cells. Immunity 2012; 37: 634-48.
25. + type 2 innate lymphoid cells. Proc Natl Acad Sci USA 2013; 110: 10240-5.
26. Furusawa J, Moro K, Motomura Y, et al., Critical role of p38 and GATA3 in natural helper cell function. J Immunol 2013; 191: 1818-26.
27. Wong SH, Walker JA, Jolin HE, et al., Transcription factor RORalpha is critical for nuocyte development. Nat Immunol 2012; 13: 229-36.
28. Fort MM, Cheung J, Yen D, et al., IL-25 induces IL-4, IL-5, and IL-13 and Th2-associated pathologies in vivo. Immunity 2001; 15: 985-95.
29. Monticelli LA, Sonnenberg GF, Abt MC, et al., Innate lymphoid cells promote lung-tissue homeostasis after infection with influenza virus. Nat Immunol 2011; 12: 1045-54.
30. Mjosberg JM, Trifari S, Crellin NK, et al., Human IL-25- and IL-33-responsive type 2 innate lymphoid cells are defined by expression of CRTH2 and CD161. Nat Immunol 2011; 12: 1055-62.
31. Licona-Limon P, Kim LK, Palm NW, et al., TH2, allergy and group 2 innate lymphoid cells. Nat Immunol 2013; 14: 536-42.
32. Cording S, Medvedovic J, Cherrier M, et al., Development and regulation of RORgammat innate lymphoid cells. FEBS Lett 2014; 588: 4176-81.
33. McHeyzer-Williams LJ, McHeyzer-Williams MG., Antigen-specific memory B cell development. Ann Rev Immunol 2005; 23: 487-513.
34. Bouskra D, Brezillon C, Berard M, Werts C, Varona R, Boneca IG, Eberl G., Lymphoid tissue genesis induced by commensals through NOD1 regulates intestinal homeostasis. Nature 2008; 456: 507-10.
35. Scandella E, Bolinger B, Lattmann E, et al., Restoration of lymphoid organ integrity through the interaction of lymphoid tissue-inducer cells with stroma of the T cell zone. Nat Immunol 2008; 9: 667-75.
36. Takatori H, Kanno Y, Watford WT, et al., Lymphoid tissue inducer-like cells are an innate source of IL-17 and IL-22. J Exp Med 2009; 206: 35-41.
37. Kim MY, McConnell FM, Gaspal FM, et al., Function of CD4+CD3- cells in relation to B- and T-zone stroma in spleen. Blood 2007; 109: 1602-10.
38. Gordon SM, Chaix J, Rupp LJ, et al., The transcription factors T-bet and Eomes control key checkpoints of natural killer cell maturation. Immunity 2012; 36: 55-67.
39. Yoshimoto T, Takeda K, Tanaka T, et al., IL-12 up-regulates IL-18 receptor expression on T cells, Th1 cells, and B cells: Synergism with IL-18 for IFN-gamma production. J Immunol 1998; 161: 3400-7.
40. Ikeda H, Old LJ, Schreiber RD., The roles of IFN gamma in protection against tumor development and cancer immunoediting. Cytokine Growth Factor Rev 2002; 13: 95-109.
41. Levy EM, Roberti MP, Mordoh J., Natural killer cells in human cancer: From biological functions to clinical applications. J Biomed Biotechnol 2011; 2011: 676198.
42. Kanegane C, Sgadari C, Kanegane H, et al., Contribution of the CXC chemokines IP-10 and Mig to the antitumor effects of IL-12. J Leukoc Biol 1998; 64: 384-92.
43. Kakkar R, Hei H, Dobner S, et al., Interleukin 33 as a mechanically responsive cytokine secreted by living cells. J Biol Chem 2012; 287: 6941-8.
44. Liew FY, Pitman NI, McInnes IB, Disease-associated functions of IL-33: The new kid in the IL-1 family. Nat Rev Immunol 2010; 10: 103-10.
45. Chackerian AA, Oldham ER, Murphy EE, et al., IL-1 receptor accessory protein and ST2 comprise the IL-33 receptor complex. J Immunol 2007; 179: 2551-5.
46. Miller AM, Asquith DL, Hueber AJ, et al., Interleukin-33 induces protective effects in adipose tissue inflammation during obesity in mice. Circ Res 2010; 107: 650-8.
47. Fujisawa T, Joshi B, Nakajima A, Puri RK., A novel role of interleukin-13 receptor alpha2 in pancreatic cancer invasion and metastasis. Cancer Res 2009; 69: 8678-85.
48. Brunner SM, Schiechl G, Falk W, Schlitt HJ, Geissler EK, Fichtner-Feigl S., Interleukin-33 prolongs allograft survival during chronic cardiac rejection. Transpl Int 2011; 24: 1027-39.
49. Gabitass RF, Annels NE, Stocken DD, et al., Elevated myeloid-derived suppressor cells in pancreatic, esophageal and gastric cancer are an independent prognostic factor and are associated with significant elevation of the Th2 cytokine interleukin-13. Cancer Immunol Immunother 2011; 60: 1419-30.
50. Wang L, Chang EW, Wong SC, et al., Increased myeloid-derived suppressor cells in gastric cancer correlate with cancer stage and plasma S100A8/A9 proinflammatory proteins. J Immunol 2013; 190: 794-804.
51. Ikutani M, Yanagibashi T, Ogasawara M, et al., Identification of innate IL-5-producing cells and their role in lung eosinophil regulation and antitumor immunity. J Immunol 2012; 188: 703-13.
52. Rosenberg HF, Phipps S, Foster PS., Eosinophil trafficking in allergy and asthma. J Allergy Clin Immunol 2007; 119: 1303-10.
53. Takatsu K, Nakajima H., IL-5 and eosinophilia. Curr Opin Immunol 2008; 20: 288-94.
54. Yamaguchi Y, Suda T, Suda J, et al., Purified interleukin 5 supports the terminal differentiation and proliferation of murine eosinophilic precursors. J Exp Med 1988; 167: 43-56.
55. Roboz GJ, Rafii S., Interleukin-5 and the regulation of eosinophil production. Curr Opin Hematol 1999; 6: 164-8.
56. Iwasaki H, Mizuno S, Mayfield R, et al., Identification of eosinophil lineage-committed progenitors in the murine bone marrow. J Exp Med 2005; 201: 1891-7.
57. Simon HU., Molecules involved in the regulation of eosinophil apoptosis. Chem Immunol Allergy 2006; 91: 49-58.
58. Mattes J, Foster PS., Regulation of eosinophil migration and Th2 cell function by IL-5 and eotaxin. Curr Drug Targets Inflamm Allergy 2003; 2: 169-74.
59. Yang M, Hogan SP, Mahalingam S, et al., Eotaxin-2 and IL-5 cooperate in the lung to regulate IL-13 production and airway eosinophilia and hyperreactivity. J Allergy Clin Immunol 2003; 112: 935-43.
60. Tepper RI, Pattengale PK, Leder P., Murine interleukin-4 displays potent anti-tumor activity in vivo. Cell 1989; 57: 503-12.
61. Simson L, Ellyard JI, Dent LA, et al., Regulation of carcinogenesis by IL-5 and CCL11: A potential role for eosinophils in tumor immune surveillance. J Immunol 2007; 178: 4222-9.
62. Nielsen HJ, Hansen U, Christensen IJ, Reimert CM, Brunner N, Moesgaard F., Independent prognostic value of eosinophil and mast cell infiltration in colorectal cancer tissue. J Pathol 1999; 189: 487-95.
63. Dorta RG, Landman G, Kowalski LP, et al., Tumour-associated tissue eosinophilia as a prognostic factor in oral squamous cell carcinomas. Histopathology 2002; 41: 152-7.
64. McHedlidze T, Waldner M, Zopf S, et al., Interleukin-33-dependent innate lymphoid cells mediate hepatic fibrosis. Immunity 2013; 39: 357-71.
65. Marvie P, Lisbonne M, L'Helgoualc'h A, et al., Interleukin-33 overexpression is associated with liver fibrosis in mice and humans. J Cell Mol Med 2010; 14: 1726-39.
66. Li J, Razumilava N, Gores GJ, et al., Biliary repair and carcinogenesis are mediated by IL-33-dependent cholangiocyte proliferation. J Clin Invest 2014; 124: 3241-51.
67. Bessho K, Bezerra JA., Biliary atresia: Will blocking inflammation tame the disease? Ann Rev Med 2011; 62: 171-85.
68. Li J, Bessho K, Shivakumar P, et al., Th2 signals induce epithelial injury in mice and are compatible with the biliary atresia phenotype. J Clin Invest 2011; 121: 4244-56.
69. Patman G., Biliary tract. IL-33, innate lymphoid cells and IL-13 are required for cholangiocyte proliferation. Nat Rev Gastroenterol Hepatol 2014; 11: 456.
70. Zhang P, Liu XK, Chu Z, et al., Detection of interleukin-33 in serum and carcinoma tissue from patients with hepatocellular carcinoma and its clinical implications. J Int Med Res 2012; 40: 1654-61.
71. Murugaiyan G, Saha B., Protumor vs antitumor functions of IL-17. J Immunol 2009; 183: 4169-75.
72. Grivennikov SI, Greten FR, Karin M., Immunity, inflammation, and cancer. Cell 2010; 140: 883-99.
73. Chan IH, Jain R, Tessmer MS, et al., Interleukin-23 is sufficient to induce rapid de novo gut tumorigenesis, independent of carcinogens, through activation of innate lymphoid cells. Mucosal Immunol 2014; 7: 842-56.
74. Pearson C, Uhlig HH, Powrie F., Lymphoid microenvironments and innate lymphoid cells in the gut. Trends Immunol 2012; 33: 289-96.
75. Geremia A, Arancibia-Carcamo CV, Fleming MP, et al., IL-23-responsive innate lymphoid cells are increased in inflammatory bowel disease. J Exp Med 2011; 208: 1127-33.
76. Langowski JL, Zhang X, Wu L, et al., IL-23 promotes tumour incidence and growth. Nature 2006; 442: 461-5.
77. Mumm JB, Oft M., Cytokine-based transformation of immune surveillance into tumor-promoting inflammation. Oncogene 2008; 27: 5913-9.
78. Grivennikov SI, Wang K, Mucida D, et al., Adenoma-linked barrier defects and microbial products drive IL-23/IL-17-mediated tumour growth. Nature 2012; 491: 254-8.
79. Kamanaka M, Huber S, Zenewicz LA, et al., Memory/effector (CD45RB(lo)) CD4 T cells are controlled directly by IL-10 and cause IL-22-dependent intestinal pathology. J Exp Med 2011; 208: 1027-40.
80. Brand S, Beigel F, Olszak T, et al., IL-22 is increased in active Crohn's disease and promotes proinflammatory gene expression and intestinal epithelial cell migration. Am J Physiol Gastrointest Liver Physiol 2006; 290: G827-38.
81. Vonarbourg C, Mortha A, Bui VL, et al., Regulated expression of nuclear receptor RORgammat confers distinct functional fates to NK cell receptor-expressing RORgammat(+) innate lymphocytes. Immunity 2010; 33: 736-51.
82. Bollrath J, Phesse TJ, von Burstin VA, et al., gp130-mediated Stat3 activation in enterocytes regulates cell survival and cell-cycle progression during colitis-associated tumorigenesis. Cancer Cell 2009; 15: 91-102.
83. Grivennikov S, Karin E, Terzic J, et al., IL-6 and Stat3 are required for survival of intestinal epithelial cells and development of colitis-associated cancer. Cancer Cell 2009; 15: 103-13.
84. Powell N, Walker AW, Stolarczyk E, et al., The transcription factor T-bet regulates intestinal inflammation mediated by interleukin-7 receptor+ innate lymphoid cells. Immunity 2012; 37: 674-84.
85. Zenewicz LA, Yancopoulos GD, Valenzuela DM, et al., Innate and adaptive interleukin-22 protects mice from inflammatory bowel disease. Immunity 2008; 29: 947-57.
86. Sugimoto K, Ogawa A, Mizoguchi E, et al., IL-22 ameliorates intestinal inflammation in a mouse model of ulcerative colitis. J Clin Invest 2008; 118: 534-44.
87. Pickert G, Neufert C, Leppkes M, et al., STAT3 links IL-22 signaling in intestinal epithelial cells to mucosal wound healing. J Exp Med 2009; 206: 1465-72.
88. Zhang W, Chen Y, Wei H, et al., Antiapoptotic activity of autocrine interleukin-22 and therapeutic effects of interleukin-22-small interfering RNA on human lung cancer xenografts. Clin Cancer Res 2008; 14: 6432-9.
89. Jiang R, Tan Z, Deng L, et al., Interleukin-22 promotes human hepatocellular carcinoma by activation of STAT3. Hepatology 2011; 54: 900-9.
90. Thompson CL, Plummer SJ, Tucker TC, et al., Interleukin-22 genetic polymorphisms and risk of colon cancer. Cancer Causes Control 2010; 21: 1165-70.
91. Ziesche E, Bachmann M, Kleinert H, et al., The interleukin-22/STAT3 pathway potentiates expression of inducible nitric-oxide synthase in human colon carcinoma cells. J Biol Chem 2007; 282: 16006-15.
92. Huber S, Gagliani N, Zenewicz LA, et al., IL-22BP is regulated by the inflammasome and modulates tumorigenesis in the intestine. Nature 2012; 491: 259-63.
93. Lim C, Savan R., The role of the IL-22/IL-22R1 axis in cancer. Cytokine Growth Factor Rev 2014 25: 257-71.
94. Savan R, McFarland AP, Reynolds DA, et al., A novel role for IL-22R1 as a driver of inflammation. Blood 2011; 117: 575-84.
95. Park O, Wang H, Weng H, et al., In vivo consequences of liver-specific interleukin-22 expression in mice: Implications for human liver disease progression. Hepatology 2011; 54: 252-61.
96. Shields JD, Kourtis IC, Tomei AA, et al., Induction of lymphoidlike stroma and immune escape by tumors that express the chemokine CCL21. Science 2010; 328: 749-52.
97. Eisenring M, vom Berg J, Kristiansen G, et al., IL-12 initiates tumor rejection via lymphoid tissue-inducer cells bearing the natural cytotoxicity receptor NKp46. Nat Immunol 2010; 11: 1030-8.